Next Issue
Volume 4, March
Previous Issue
Volume 3, September
 
 

Sclerosis, Volume 3, Issue 4 (December 2025) – 10 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
18 pages, 639 KB  
Systematic Review
Extrapyramidal Movement Disorders in Multiple Sclerosis Patients: A Systematic Review
by Mai M. Anwar, Rosie Heartshorne and Sundus H. Alusi
Sclerosis 2025, 3(4), 42; https://doi.org/10.3390/sclerosis3040042 - 16 Dec 2025
Viewed by 70
Abstract
Background: Although multiple sclerosis (MS)-associated tremor and ataxia are well described in the neurological literature, other extrapyramidal movement disorders (MDs), including Holmes tremor, dystonia, chorea, myoclonus, parkinsonism, and restless legs syndrome, have received far less attention and are generally regarded as rare [...] Read more.
Background: Although multiple sclerosis (MS)-associated tremor and ataxia are well described in the neurological literature, other extrapyramidal movement disorders (MDs), including Holmes tremor, dystonia, chorea, myoclonus, parkinsonism, and restless legs syndrome, have received far less attention and are generally regarded as rare manifestations of MS. Rationale: Although MS is traditionally considered a white matter disease, increasing evidence has demonstrated clinically relevant grey matter involvement, particularly within the basal ganglia, thalamus, and cerebellar–brainstem pathways. Understanding extrapyramidal MDs in MS may therefore provide important insights into the functional networks disrupted by demyelination and inflammation. Aim: This review aims to highlight the available literature on extrapyramidal MDs in MS, outlining their clinical presentations, lesion correlates, and proposed mechanisms. We examined reported cases, reviews, and findings in the literature explaining these disorders and their occurrence in association with acute relapses, as well as their development during the progressive phase of MS. Conclusions: By integrating clinical and pathophysiological evidence, this review highlights how rare extrapyramidal MDs may reflect underlying grey matter pathology and network-level disruption, with potential implications for diagnosis, monitoring, and treatment. Full article
Show Figures

Figure 1

11 pages, 753 KB  
Systematic Review
Risk Factors for Relapses in Multiple Sclerosis Beyond Disease-Modifying Therapy: An Umbrella Review of Systematic Reviews and Meta-Analyses
by Sara Terrim, Samira Luisa Apostolos-Pereira, Thiago Ivan Vilchez Santillan, Tarso Adoni, Dagoberto Callegaro and Guilherme Diogo Silva
Sclerosis 2025, 3(4), 41; https://doi.org/10.3390/sclerosis3040041 - 10 Dec 2025
Viewed by 180
Abstract
Background/Objectives: People with MS continue to experience relapses despite the use of disease-modifying therapies. This has motivated growing interest in the potential of non-pharmacological factors to reduce relapse risk. However, previous studies have been heterogeneous, and current clinical guidelines lack clarity on which [...] Read more.
Background/Objectives: People with MS continue to experience relapses despite the use of disease-modifying therapies. This has motivated growing interest in the potential of non-pharmacological factors to reduce relapse risk. However, previous studies have been heterogeneous, and current clinical guidelines lack clarity on which measures should be incorporated into routine care. We aim to conduct an umbrella review of systematic reviews with meta-analyses to determine the current evidence on non-pharmacological exposures associated with relapse risk in MS. Methods: We searched PubMed, Embase and Cochrane to identify systematic reviews with meta-analyses that evaluated the association between non-pharmacological exposures and relapse risk. We included observational studies that reported on relapses as an outcome. The effect sizes (relative risk [RR] or standardized mean difference [SMD]) and certainty of evidence were assessed using components of the GRADE framework. Results: We screened 3366 articles and identified 11 systematic reviews for inclusion. Protective factors were breastfeeding (RR 0.63, high certainty), pregnancy (SMD −0.52, moderate certainty), menopause (SMD −0.5, low certainty), autumn months (RR 0.97, moderate certainty) and increasing levels of vitamin D (RR 0.9, low certainty). Risk factors were early postpartum period (RR 1.87, moderate certainty) and stress (d = 0.53, moderate certainty). Influenza vaccination (low certainty), COVID-19 infection (low certainty), and vitamin D levels above 50 nmol/L (low certainty) were not statistically associated with relapse risk. Conclusions: Our umbrella review highlights the need for more robust studies to strengthen the certainty of evidence on non-pharmacological exposures and relapse risk in people with MS. Current findings support promoting breastfeeding, careful disease management throughout the pregnancy–postpartum period, and the implementation of stress mitigation strategies. Full article
(This article belongs to the Special Issue Advances in Multiple Sclerosis: From Pathogenesis to Therapeutics)
Show Figures

Figure 1

16 pages, 963 KB  
Review
Recent Advances in Localized Scleroderma
by Toshiya Takahashi, Takehiro Takahashi and Yoshihide Asano
Sclerosis 2025, 3(4), 40; https://doi.org/10.3390/sclerosis3040040 - 2 Dec 2025
Viewed by 631
Abstract
Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse. This review summarizes recent advances in the understanding and management of [...] Read more.
Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse. This review summarizes recent advances in the understanding and management of LSc. Pathophysiological insights have evolved significantly; the somatic mosaicism hypothesis is now supported by the observation of all six of Happle’s classic lesion patterns in LSc. Furthermore, recent single-cell RNA sequencing has elucidated key cellular mechanisms, revealing an IFN-γ-driven pro-fibrotic crosstalk between T cells, dendritic cells, and specific inflammatory fibroblast subpopulations. The discovery of a rare monogenic form of LSc caused by a STAT4 gain-of-function mutation provides a powerful human model, solidifying the critical role of the JAK-STAT pathway. Clinically, LSc is classified into subtypes such as circumscribed, linear, and generalized morphea. Extracutaneous manifestations are common, particularly in juvenile LSc, and are associated with higher disease activity and reduced quality of life, necessitating a multidisciplinary approach. Management is becoming standardized, with methotrexate as the first-line systemic therapy for severe disease. For refractory cases, targeted treatments including abatacept, tocilizumab, and JAK inhibitors are emerging as promising options. In addition, reconstructive therapies like autologous fat grafting are crucial for managing atrophic sequelae. These recent advances are paving the way for more effective, targeted therapies to improve outcomes for patients with this complex disease. Full article
(This article belongs to the Special Issue Advances in Systemic Sclerosis Research in Japan)
Show Figures

Figure 1

12 pages, 877 KB  
Article
Cognitive Impairment Screening in Multiple Sclerosis Using CoGeval: Clinical and Functional Predictors in a Mexican Cohort
by Luis F. Hernández Salomón, José A. Mejía Chávez, Diana M. S. Sánchez Galván and Luis E. Zapata Mercado
Sclerosis 2025, 3(4), 39; https://doi.org/10.3390/sclerosis3040039 - 29 Nov 2025
Viewed by 243
Abstract
Background/Objectives: Cognitive impairment is frequent in multiple sclerosis, yet routine screening is inconsistently implemented. We aimed to characterize cognitive impairment using CogEval in a Mexican cohort and to identify clinical and functional correlates. Methods: We conducted a cross-sectional study at UMAE No. 71 [...] Read more.
Background/Objectives: Cognitive impairment is frequent in multiple sclerosis, yet routine screening is inconsistently implemented. We aimed to characterize cognitive impairment using CogEval in a Mexican cohort and to identify clinical and functional correlates. Methods: We conducted a cross-sectional study at UMAE No. 71 (Torreón, Mexico). Adults with MS (n = 81) underwent CogEval screening (classified as normal, mild, or severe). Disability, upper-limb dexterity (9-Hole Peg Test, mean of both hands), and gait speed (Timed 25-Foot Walk) were assessed. Bivariate tests and multivariable logistic regression examined associations with cognitive impairment. Results: Participants were 61.7% women; mean age was 35.7 ± 9.9 years. Median EDSS was 2.0 (IQR 1.0–4.0); 28.4% had EDSS ≥ 4. CogEval identified impairment in 49.4% (40/81), with 62.5% severe and 37.5% mild. In bivariate analyses, impairment was associated with higher EDSS (p < 0.001), slower 9-HPT (p < 0.001), and slower T25FW (p = 0.0058), but not with age, sex, or disease duration. In adjusted models, EDSS (OR 1.86, 95% CI 1.14–3.03; p = 0.012) and 9-HPT per second (OR 1.31, 95% CI 1.09–1.58; p = 0.005) independently predicted impairment, whereas T25FW and age were not significant. Discrimination was good (AUC = 0.863). Conclusions: About half of this Mexican MS cohort screened positive for cognitive impairment, particularly those with greater disability and reduced manual dexterity. CogEval appears feasible for routine screening and may help prioritize comprehensive neuropsychological assessment and rehabilitation. Full article
Show Figures

Figure 1

24 pages, 1118 KB  
Article
Fingolimod and Neuroinflammation in MS: Representing CD8+ T-Cell Dynamics Through Mathematical Modeling and Clinical Evidence
by Gabriela M. Gazola, João Víctor Costa de Oliveira, Matheus A. M. de Paula, Barbara M. Quintela and Marcelo Lobosco
Sclerosis 2025, 3(4), 38; https://doi.org/10.3390/sclerosis3040038 - 28 Nov 2025
Viewed by 266
Abstract
Background: Multiple sclerosis (MS), a debilitating chronic disease of the central nervous system, is characterized by both inflammatory and neurodegenerative processes that lead to demyelination and neuronal damage. While MS remains incurable, therapies like fingolimod can slow disease progression by modulating immune [...] Read more.
Background: Multiple sclerosis (MS), a debilitating chronic disease of the central nervous system, is characterized by both inflammatory and neurodegenerative processes that lead to demyelination and neuronal damage. While MS remains incurable, therapies like fingolimod can slow disease progression by modulating immune function. Fingolimod acts as a sphingosine-1-phosphate receptor modulator, limiting lymphocyte migration into the central nervous system and thereby reducing inflammation. Methods: In this study, we developed a computational model to describe fingolimod’s impact on immune dynamics in MS, focusing on CD8+ T-cell migration blockade. Model calibration utilized cohort data, enabling the comparison of simulated outcomes with observed clinical metrics. Results: The results indicate that our model effectively captures the timing and extent of CD8+ T-cell sequestration, consistent with key features in the patient data. Conclusions: These findings suggest that computational modeling can provide quantitative insight into the fingolimod’s mechanism of action and assist in predicting treatment response, offering a promising framework for exploring personalized fingolimod dosing strategies and enhancing therapeutic planning in MS. Full article
Show Figures

Figure 1

13 pages, 1368 KB  
Article
Exploring the Links Between Ankylosing Spondylitis and Amyotrophic Lateral Sclerosis: A Bidirectional Mendelian Randomization Study
by Adeyemi Timothy Akinade, Ezekiel Damilare Jacobs, Chucks Marvellous Obere, Victor Omeiza Ogaji, Emmanuel Alakunle and Olaitan I. Awe
Sclerosis 2025, 3(4), 37; https://doi.org/10.3390/sclerosis3040037 - 16 Nov 2025
Viewed by 417
Abstract
Background: Very few case reports have explored a potential link between ankylosing spondylitis (AS), an autoimmune disorder, and amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative condition. We aimed to investigate whether genetic liability to AS causally influences the risk of ALS, and vice [...] Read more.
Background: Very few case reports have explored a potential link between ankylosing spondylitis (AS), an autoimmune disorder, and amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative condition. We aimed to investigate whether genetic liability to AS causally influences the risk of ALS, and vice versa, using a bidirectional two-sample Mendelian randomization (MR) framework. Methods: We performed a two-sample MR study to evaluate the bidirectional causal relationship between genetic liability to ankylosing spondylitis and ALS risk. We used 6 valid single nucleotide polymorphisms (SNPs) from genome-wide association study (GWAS) data (AS: 1462 cases and 164,682 controls; ALS: 27,205 cases and 110,881 controls). We used the inverse-variance weighted (IVW) approach as the primary statistical method for causal estimation, with sensitivity analyses (including MR-Egger, weighted median, weighted mode, Mendelian Randomization Pleiotropy Residual Sum and Outlier (MR-PRESSO), leave-one-out, and single SNP analysis) to assess pleiotropy and heterogeneity. Results: There was no evidence of a causal association between genetic predispositions to ankylosing spondylitis (AS) and amyotrophic lateral sclerosis (ALS) (IVW OR = 1.01; 95% CI: 0.99–1.02; p = 0.10). The results from the weighted median, weighted mode, MR-Egger, and simple mode methods were consistent and nonsignificant. In the reverse analysis, genetic liability to ALS showed no causal effect on AS (IVW OR = 0.88; 95% CI: 0.70–1.12; p = 0.33), with similar null findings across all sensitivity methods. Conclusions: Overall, our bidirectional two-sample MR analyses provided no evidence supporting a causal relationship between AS and ALS. Full article
Show Figures

Figure 1

12 pages, 233 KB  
Article
Workplace Adjustment Measures to Maintain the Ability to Work of People with Multiple Sclerosis
by Mona-Elisa Eberharter and Harald Stummer
Sclerosis 2025, 3(4), 36; https://doi.org/10.3390/sclerosis3040036 - 6 Nov 2025
Viewed by 369
Abstract
Background: Multiple sclerosis (MS) leads to early retirement in one-third of patients. The aim of this study is to analyze the difficulties at work and to collect suggestions for support measures at the workplace to maintain the ability to work for people with [...] Read more.
Background: Multiple sclerosis (MS) leads to early retirement in one-third of patients. The aim of this study is to analyze the difficulties at work and to collect suggestions for support measures at the workplace to maintain the ability to work for people with MS. Methods: Qualitative interviews were conducted with 20 people affected by MS. The participants’ experiences with workplace support were summarized and suggestions for workplace measures were presented. Results: Lack of offers of health-related measures and missing adjustments of the workplace has been analyzed. Offering flexible working hours and measures against fatigue is desired. Intensifying the cooperation between labor market service, health care providers and companies can help reintegrate affected people. Conclusions: Workplace education about MS and health-related measures is needed. Technical adaptations and flexible working hours can support in maintaining workability. Measures against fatigue must be developed and companies must set further measures to support people with illnesses. Full article
13 pages, 490 KB  
Article
Evaluation of Early Initiation of Disease-Modifying Treatment for Patients with Multiple Sclerosis Within a Real-World Population for Long-Term Outcomes
by Menai McDonald, Angus D. Macleod and Paul Gallagher
Sclerosis 2025, 3(4), 35; https://doi.org/10.3390/sclerosis3040035 - 28 Oct 2025
Viewed by 562
Abstract
Background: There is varied practice with Disease-Modifying Treatment (DMT) for Multiple Sclerosis worldwide. We evaluated early DMT initiation within a real-world population for long-term outcomes. Method: The Scottish Multiple Sclerosis Register (SMSR) identified participants diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS) in 2010/2011. [...] Read more.
Background: There is varied practice with Disease-Modifying Treatment (DMT) for Multiple Sclerosis worldwide. We evaluated early DMT initiation within a real-world population for long-term outcomes. Method: The Scottish Multiple Sclerosis Register (SMSR) identified participants diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS) in 2010/2011. We compared two groups of propensity-matched participants at diagnosis, who went on to receive either early treatment (<12 months from diagnosis) or late/never treated. Participants underwent detailed clinicoradiological evaluation and patient-reported outcome measures 11–13 years post-diagnosis. The primary outcome was mean Expanded Disability Status Scale (EDSS). Results: The SMSR identified 298 participants. A total of 141 had complete retrospective clinical data and 81 agreed to participate, with 32 successfully matched (16 pairs). Median time on DMT was 10.8 years (range 0.4–12.5) for those treated early and 4.0 (0–11.5) years for the late/never-treated group. A total of 7/16 (44%) never received a DMT of those not treated early. All early-treated participants commenced first-line DMT (5/16 subsequently escalated to second-line DMTs). Of those treated later (9/16), 7/9 participants (78%) commenced first-line and 2/9 s-line DMT. There were no serious adverse events identified with any DMT. There was no significant difference in the primary outcome, with mean EDSS 3.93 in the late/never-treated group vs. 4.53 in the early-treated group at 11–13 years post-diagnosis (p = 0.57). There was no significant difference in median change in EDSS from the time of diagnosis to prospective assessment between early and late/never-treated groups. Patient Reported Outcome Measurement Information System (PROMIS) scores for cognition favoured no early treatment (p = 0.02), whilst satisfaction with treatment choice favoured early treatment (p = 0.03). Conclusions: Our cohort did not show clear benefit with early DMT in RRMS, contrasting with other larger studies, with no significant differences between early and late/never-treated patients on clinicoradiological outcomes. Possible explanations include confounding by variables not included in matching and group allocation based on diagnosis date rather than first clinical symptom. Most participants were treated with injectable DMTs, not in keeping with current practice. A prospective, long-term follow-up deep phenotyping study would help characterise benefits of early DMT use, but this is clearly challenging in practice. Full article
Show Figures

Figure 1

8 pages, 301 KB  
Communication
Possible Reasons for the Suboptimal Response of the Cladribine Course in Daily Practice: An Independent Analysis of Data from 12 Russian Clinics and the Results of Post-Registration Studies in Other Countries
by Alexey N. Boyko, Valentina M. Alifirova, Daria V. Pashkovskaya, Ekaterina I. Kuchina, Stella A. Sivertseva, Elena L. Turova, Zoya A. Goncharova, Olga Yu Rudenko, Yulia Yu Pogrebnova, Farid A. Khabirov, Timur I. Khaibullin, Natalia N. Babicheva, Natalia L. Khoroshilova, Oksana V. Dzundza, Olga A. Soldatova, Anna N. Belova, Gennadyi E. Sheiko, Anastasia E. Makarova and Natalia G. Glavinskaya
Sclerosis 2025, 3(4), 34; https://doi.org/10.3390/sclerosis3040034 - 24 Oct 2025
Viewed by 488
Abstract
Objectives: The purpose of this study was to analyze the effect of daily intake of cladribine tablets on the course of multiple sclerosis (MS) while monitoring for 1–4 years during and after the course in several neurological clinics from different regions of the [...] Read more.
Objectives: The purpose of this study was to analyze the effect of daily intake of cladribine tablets on the course of multiple sclerosis (MS) while monitoring for 1–4 years during and after the course in several neurological clinics from different regions of the Russian Federation. Materials and Methods: Information was collected on 235 patients from 12 neurological clinics and regional centers for MS, who were observed for an average of 3.4 years after starting treatment with cladribine. Results: An independent analysis of cases of prescription of cladribine in tablets showed that the reason for prescription of cladribine was highly active MS (HAMS) in 159 patients (67.7%), rapidly progressive MS (RPMS) in 20 patients (8.5%), active remitting MS in 50 patients (21.3%) and secondary progressive MS (SPMS) with exacerbations in 6 (2.5%). Among them, only 12 patients (5.1%) had not previously received DMTs, i.e., in these cases, the drug was prescribed as the first DMT. In total, 22 patients had previously received natalizumab, 5—ocrelizumab, and in 1 case—fingolimod. The remaining 207 patients were crossed over from the first-line DMTs. In all cases, there was a decrease in the frequency of exacerbations during and after the completion of the course of cladribine. Exacerbations between the first and second courses of cladribine were noted in 36 patients (15.3% of all treated), almost half of the cases—those who previously received natalizumab (17 exacerbations, or 47.2% of all exacerbations between the 1st and 2nd courses of cladribine), and in 3 cases—from ocrelizumab (in 60% of all patients crossed over from ocrelizumab). During 4 years of follow-up after a full course of cladribine, exacerbations were in 14 patients (6% of all patients included in the analysis), of which in 6 cases—after crossover from natalizumab. Discussion and Conclusions: The data obtained are generally consistent with the results of meta-analyses and reviews published recently, but high probability of exacerbations in patients who were crossed over from second-line drugs such as natalizumab and ocrelizumab were seen. The crossover from natalizumab is carried out more often due to the increased risk of developing progressive multifocal encephalopathy (PML). It is likely that the restoration of MS activity after the withdrawal of natalizumab is quite frequent, cladribine tablets were not able to fully prevent this. Such a crossover does not seem to be optimal, unlike the crossover from first-line DMTs. If such a crossover is still planned, it could be performed within 4 weeks after stopping natalizumab. Full article
28 pages, 2032 KB  
Review
Antithrombotic and Anti-Inflammatory Health Promoting Pharmacological Properties of Chalcones and Their Derivatives Against Atherosclerosis and CVD
by Valeria Katsoti, Anna Ofrydopoulou and Alexandros Tsoupras
Sclerosis 2025, 3(4), 33; https://doi.org/10.3390/sclerosis3040033 - 24 Oct 2025
Viewed by 1145
Abstract
Chalcones, a class of flavonoid compounds, are recognized for their unique biological properties, and especially for their antithrombotic, anti-inflammatory, and antioxidant health-promoting properties against inflammation-related disorders. Chalcones are phytochemicals naturally found in plants, fruits, and vegetables, such as tomatoes, apples, and licorice. Their [...] Read more.
Chalcones, a class of flavonoid compounds, are recognized for their unique biological properties, and especially for their antithrombotic, anti-inflammatory, and antioxidant health-promoting properties against inflammation-related disorders. Chalcones are phytochemicals naturally found in plants, fruits, and vegetables, such as tomatoes, apples, and licorice. Their characteristic chemical structure, which includes two aromatic rings and an α,β-unsaturated carbonyl group, makes them particularly versatile for pharmaceutical use. At the same time, chalcones exhibit strong antioxidant activity by neutralizing free radicals and enhancing endogenous antioxidant defense systems, such as glutathione. Structural modifications have improved their biological activity, leading to important applications in the treatment of atherosclerosis and cardiovascular diseases, cancer, neurodegenerative diseases, and inflammatory disorders. In addition, they have been successfully used in agriculture as natural pesticides and in the food industry as antioxidant additives. This review demonstrates the interdisciplinary importance of chalcones, highlighting the need for further research into their molecular mechanisms of action. A deeper understanding of their properties may open new avenues for the development of innovative drugs and environmentally friendly applications. In this way, chalcones can be a decisive factor in improving human health and environmental sustainability. Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop